Cargando…

The challenge of targeting metastasis

Metastases that are resistant to conventional therapy are the major cause of death from cancer. In most patients, metastasis has already occurred by the time of diagnosis. Thus, the prevention of metastasis is unlikely to be of therapeutic benefit. The biological heterogeneity of metastases presents...

Descripción completa

Detalles Bibliográficos
Autores principales: Fidler, Isaiah J., Kripke, Margaret L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661188/
https://www.ncbi.nlm.nih.gov/pubmed/26328524
http://dx.doi.org/10.1007/s10555-015-9586-9
_version_ 1782402935159783424
author Fidler, Isaiah J.
Kripke, Margaret L.
author_facet Fidler, Isaiah J.
Kripke, Margaret L.
author_sort Fidler, Isaiah J.
collection PubMed
description Metastases that are resistant to conventional therapy are the major cause of death from cancer. In most patients, metastasis has already occurred by the time of diagnosis. Thus, the prevention of metastasis is unlikely to be of therapeutic benefit. The biological heterogeneity of metastases presents a major obstacle to treatment. However, the growth and survival of metastases depend on interactions between tumor cells and host homeostatic mechanisms. Targeting these interactions, in addition to the tumor cells, can produce synergistic therapeutic effects against existing metastases.
format Online
Article
Text
id pubmed-4661188
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-46611882015-12-04 The challenge of targeting metastasis Fidler, Isaiah J. Kripke, Margaret L. Cancer Metastasis Rev Non-Thematic Review Metastases that are resistant to conventional therapy are the major cause of death from cancer. In most patients, metastasis has already occurred by the time of diagnosis. Thus, the prevention of metastasis is unlikely to be of therapeutic benefit. The biological heterogeneity of metastases presents a major obstacle to treatment. However, the growth and survival of metastases depend on interactions between tumor cells and host homeostatic mechanisms. Targeting these interactions, in addition to the tumor cells, can produce synergistic therapeutic effects against existing metastases. Springer US 2015-09-02 2015 /pmc/articles/PMC4661188/ /pubmed/26328524 http://dx.doi.org/10.1007/s10555-015-9586-9 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Non-Thematic Review
Fidler, Isaiah J.
Kripke, Margaret L.
The challenge of targeting metastasis
title The challenge of targeting metastasis
title_full The challenge of targeting metastasis
title_fullStr The challenge of targeting metastasis
title_full_unstemmed The challenge of targeting metastasis
title_short The challenge of targeting metastasis
title_sort challenge of targeting metastasis
topic Non-Thematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661188/
https://www.ncbi.nlm.nih.gov/pubmed/26328524
http://dx.doi.org/10.1007/s10555-015-9586-9
work_keys_str_mv AT fidlerisaiahj thechallengeoftargetingmetastasis
AT kripkemargaretl thechallengeoftargetingmetastasis
AT fidlerisaiahj challengeoftargetingmetastasis
AT kripkemargaretl challengeoftargetingmetastasis